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Background: Conventional screening for hypothyroidism is controversial. Although hypothyroidism is
underdiagnosed, many organizations do not recommend screening, citing low disease prevalence in unselected
populations. We studied attendees at a thyroid health fair, hypothesizing that certain patient characteristics would
enhance the yield of testing.
Methods: We carried out an observational study of participants at a Michigan health fair that focused on thyroid
disease. We collected patient-reported symptoms and demographics by questionnaire, and correlated these with
the TSH values obtained through the health fair.
Results: 794 of 858 health fair attendees participated. Most were women, and over 40% reported a family history of
thyroid disease. We identified 97 (12.2%) participants with previously unknown thyroid dysfunction. No symptom or
combination of symptoms discriminated between hypothyroid and euthyroid individuals. Hypothyroid and
euthyroid participants in the health fair reported each symptom with a similar prevalence (p > 0.01), a prevalence
which was very high. In fact, when compared with a previously published case-control study that reported
symptoms, the euthyroid health fair participants reported a higher symptom prevalence (range 3.9% to 66.3%,
mean 31.5%), than the euthyroid individuals from the case-control study (range 2% to 54%, mean 17.4%).
Conclusions: A high proportion of previously undiagnosed thyroid disease was identified at this health fair. We
initially hypothesized symptoms would distinguish between thyroid function states. However, this was not the case
in this health fair screening population. The prevalence of reported symptoms was similar and high in both
euthyroid and hypothyroid participants. Because attendees were self-selected, it is possible that this health fair that
focused on thyroid disease attracted participants specifically concerned about thyroid health. Despite the lack of
symptom discrimination, the much higher prevalence of hypothyroidism in this study (12%) compared with the
general population (<2%) suggests that screening may be appropriate and effective in certain circumstances such
as thyroid health fairs.
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Health promotion and disease prevention continue to gain
emphasis in the evolving U.S. health care system. Even the
Centers for Medicare and Medicaid Services (CMS) have
embraced screening. The annual wellness exam is now a
covered Medicare benefit, and screening tests such as
bone densitometry are prescribed quality measures for the
Physician Quality Reporting Initiative (PQRI) [1,2].* Correspondence: gcanaris@unmc.edu
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reproduction in any medium, provided the orHealth Fairs are a frequent fixture in health promotion
programs. The intent is to detect treatable diseases early
to improve the health of the community. Health fairs have
historically been part of community service programs, effi-
ciently using resources to reach large numbers of people.
More recently, health fairs have included more specialized
screenings of certain diseases in focused populations [3,4].
Health fairs do have the potential for data collection, but
this is rarely done in a systematic fashion. In part, this
may be because health fair populations are not alwaysLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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attendees tend to be older when compared with the
general population, likely because older retirees have more
time to participate in such programs. Health fairs also
tend to attract more women than men, as is the case with
health care in general [5-9].
Health fairs may offer screening and information on
multiple medical topics, or focus on a certain disease. One
specialized screening offered by some health fairs is testing
for thyroid disease. The prevalence of thyroid dysfunction
in the general population is estimated between 1 and 2%
[10]. For the individual person affected with thyroid
disease, the disorder affects almost every organ system in
the body. Functional thyroid disease is divided into
hypothyroidism (underactive thyroid) and hyperthyroid-
ism (overactive thyroid). With the development of assays
that accurately measure thyroid hormone levels, these
categories have been further subdivided into overt and
subclinical disease. The classification is a misnomer in
that clinical symptoms are not what distinguish subclinical
disease. Rather, subclinical disease is defined by an abnor-
mal TSH but normal free T4 level. In overt disease, both
the TSH and free T4 levels are abnormal. The vast major-
ity of thyroid dysfunction is hypothyroidism [10-12], so
that hypothyroidism is often the focus of screening
programs such as health fairs.
Many people with thyroid problems such as
hypothyroidism go undiagnosed [12]. Symptoms develop
gradually and are so nonspecific [13], that thyroid disease
is not suspected and individuals may not seek medical
attention. Screening for thyroid disease would therefore
seem appropriate. Yet, many organizations recommend
against general population screening for thyroid dysfunc-
tion. The U.S. Preventive Services Task Force, for example,
states that “the yield of screening is greater in certain
high-risk groups”, but does not recommend for or against
routine screening for thyroid disease in asymptomatic
adults [14]. However, individual symptoms associated with
hypothyroidism are often unrecognized as such, making it
difficult to identify the “symptomatic adult” [13]. Several
groups do support screening among higher risk groups,
such as women and older individuals, to increase the yield
of testing [15,16].
One of the authors (GJC) obtained permission to collect
data at a thyroid screening health fair in Michigan. The
initial goal was to study the symptoms of those with and
without thyroid disease in order to identify characteristics
which increase the likelihood of an individual to have
thyroid disease. A secondary goal was to determine the
yield of thyroid screening in this population as compared
with previous studies. We hypothesized that certain self-
reported patient characteristics would increase the likeli-
hood of thyroid disease, thus directing higher yield thyroid
screening in the future.Methods
“Thyroid Awareness Week” was sponsored by St. Mary’s
Health Services of Grand Rapids, Michigan, in conjunc-
tion with Boots Pharmaceutical Company. As part of
Thyroid Awareness Week, information on thyroid disease
was dispersed through radio, television and the press. A
local endocrinologist lectured on thyroid disease, and
thyroid function test screening was offered following the
lecture. The screening activities were available at multiple
locations and various times throughout the week.
The Health Fair offered thyroid function blood testing
to anyone who presented to one of seven thyroid screen-
ing sites. The blood test used was the third generation
supersensitive thyroid stimulating hormone (Ciba-
Corning Diagnostics Corporation, Automated Chemilu-
minescence System assay) for a $5.00 charge through the
Health Fair. This TSH assay has a normal range of
0.4 – 5.5 μIU/ml. Thyroxine (free T4) levels were not
offered by the health fair.
Permission was obtained to carry out an observational
study of participants in this health fair focused on testing
for thyroid dysfunction. Data was collected at the Thyroid
Awareness Week screening locations using a self-
administered questionnaire. Each adult participant, age 18
and older, was asked to complete the Thyroid Symptoms
Questionnaire to assess symptoms and obtain demo-
graphic information. This questionnaire was developed by
one of the authors and has been used in other studies
[12,13]. The questionnaire asked about the presence and
severity of symptoms traditionally associated with thyroid
disease, and if these symptoms had changed over the
preceding year. Demographic information included age
and gender, medications, and personal and family history
of thyroid disease. The questionnaire took between five
and ten minutes to complete.
Informed consent was obtained from each individual
who wished to participate in the screening and complete
the questionnaire. Informed consent included permission
to obtain the individual’s TSH result from the health fair
in order to link the TSH level to the questionnaire
responses. Approval of the project was obtained from the
sponsors of Thyroid Awareness Week, St. Mary’s Hospital
Institutional Review Committee, and from the
Butterworth Hospital Research and Human Rights
Committee (the first author’s affiliation at the time).
Results of the TSH were provided to each participant with
instructions to share the information, regardless of result,
with their health care provider.
Data and statistical analysis
Data were analyzed using SAS statistical software, (SAS
Institute, Inc. Cary, North Carolina). We applied the chi
square test to compare proportions. Thyroid function
was defined by the normal range of the TSH assay,
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as a TSH > 5.5 μIU/ml, and hyperthyroidism as a
TSH < 0.4 μIU/ml.
We used logistic regression to examine the effect on
TSH levels of age and family history in combination with
each symptom. Regression was run with age and family
history and the 33 symptom variables entered as inde-
pendent variables. TSH as the dependent variable was
analyzed at two thresholds. We analyzed the data using
two different TSH thresholds, (greater than 5.5 μIU/ml
the upper limit of the normal range for this assay, and
greater than 10 μIU/ml), to test the hypothesis that symp-
toms become useful only in more severe disease. This is a
threshold that has been applied in other studies to explore
potential differences in what may be biochemically more
advanced disease [17-20]. We also evaluated TSH as a
continuous variable. The association between thyroid
function (as measured by TSH) and symptoms was
measured using the Spearman Rank-Order Correlation.
Pearson Correlation Coefficient and linear regression was
used to evaluate the association between TSH and the
number of symptoms reported by any individual. Due to
multiple comparisons, the more conservative threshold of
p < 0.01 was used as the criterion for statistical signifi-
cance throughout this study.
Results
858 people presented to one of the seven thyroid screen-
ing sites. Sixty-four individuals were excluded from ana-
lysis for the following reasons: 41 (4.8%) did not return
the questionnaire and/or demographic sheet, 7 (0.8%)
were under age 18, and 16 (1.9%) completed fewer than
75% of the questionnaire responses. This left 794 partici-
pants for analysis (Tables 1 and 2). More women than
men participated and the mean age of participants
(51.9 years) was greater than that of the general popula-
tion (30.0 years), features which are common to health
fairs in general.
Participants were categorized as hypothyroid, euthyroid
or hyperthyroid using the supersensitive TSH assay with
normal range 0.4 – 5.5 μIU/ml. People with a TSH level
greater than 5.5 μIU/ml were classified as hypothyroid,
and those with a TSH level less than 0.4 μIU/ml were
classified as hyperthyroid. Free T4 levels were not available
through the Health Fair to further subclassify thyroid
function regarding subclinical disease. TSH levels ranged
from undetectable (<0.03 μIU/ml) to 582 μIU/ml with the
following distribution: the 50th percentile corresponded
to a TSH of 2.2 μIU/ml, the 75th percentile to a TSH
of 3.7 μIU/ml and the 90th percentile to a TSH of
6.7 μIU/ml.
One-hundred forty-eight people had an abnormal TSH
in this study (Table 3). Fifty-one (34.0%) of the 148 had
known thyroid disease, so were not in the therapeuticrange on their current medication. The remaining ninety-
seven previously undiagnosed individuals, 12.2% of the
total screened population, were identified through this
screening program as having thyroid disease. Most of the
thyroid disease detected (79.4%) was hypothyroidism.
Thirty-three of the ninety-seven (34.0%) who were previ-
ously undiagnosed had a TSH greater than 10 μIU/ml.
Of the 794 evaluable participants, 108 (13.6%) reported
being on a thyroid medication. (Two of these listed their
thyroid medication as an over-the-counter herbal supple-
ment rather than a prescription thyroid hormone replace-
ment; consequently 106 was the denominator used in
analysis.) Of those taking thyroid medication, 94 (88.7%)
were women and 12 (11.3%) were men. Three of the
12 men had a TSH less than 0.4 μIU/ml so were over-
replaced, that is, on too high of a dose of thyroid hormone
replacement putting the person in the hyperthyroid range.
Three were under-replaced, or on too low of a dose of
thyroid hormone with TSH greater than 5.5 μIU/ml. Six
were in the euthyroid range. Ninety-four (14.5%) women
reported taking thyroid medication; 23 were over-replaced
on their medication so in the hyperthyroid range, 22 were
under-replaced so in the hypothyroid range, so that only
49 (52.1%) were biochemically euthyroid.
Among the 97 participants without a previously known
diagnosis of thyroid disease, 77 (9.7%) were hypothyroid
and 20 (2.5%) were hyperthyroid. Seventy-eight were
women and 19 were men. Of the nineteen men, thirteen
had hypothyroidism and six were hyperthyroid. Of the
women, 64 were diagnosed with hypothyroidism and four-
teen with hyperthyroidism. Regarding family history,
290 women and 44 men reported a family history of
thyroid disease (Tables 1 and 2). The breakdown of family
history among disease states showed that 41.8% of euthyr-
oid individuals reported a positive family history as
compared with 45.0% of hypothyroid individuals reporting
family history and 45.7% of hyperthyroid individuals
reporting family history (p value = 0.75). Having family
history of thyroid disease did not distinguish between
euthyroidism and thyroid dysfunction.
The reported prevalence of individual symptoms in this
health fair population was high (Additional file 1). The
prevalence with which an individual symptom was reported
by participants with hypothyroidism was similar to the
prevalence reported by those without hypothyroidism, (not
statistically significantly different, p > 0.01). The symptom
prevalence reported by health fair participants whether
hypothyroid or euthyroid, exceeded the prevalence reported
by euthyroid controls in a previously published case-
control study [13]. Euthyroid health fair participants’ symp-
tom prevalence ranged from 3.9% to 66.3% (mean 31.5%),
in fact higher than in the previous case-control study of the
general population where euthyroid individuals reported
symptom prevalence between 2% and 54% (mean 17.4%)
Table 1 Demographics of evaluable subjects
Men Women Total
Number (%) of participants 147 (18.5) 647 (81.5) 794 (100)
Age range (mean) in years 20 – 86 (56.6) 20 – 87 (50.9) 20 – 87 (51.9)
Number (%) reporting a family history of thyroid disease 44 (30.3) 290 (45.2) 334 (42.4)
Range of TSH values in μIU/ml < 0.03 – 582 < 0.03 – 128 < 0.03 – 582
50th percentile (TSH in μIU/ml) 2.2
75th percentile (TSH in μIU/ml) 3.7
90th percentile (TSH in μIU/ml) 6.7
Number (%) of TSH < 0.4 μIU/ml 9 (6.1) 37 (5.7) 46 (5.8)
Number (%) of TSH > 5.5 μIU/ml 16 (10.9) 86 (13.3) 102 (12.8)
Number (%) of TSH > 10 μIU/ml 6 (4.1) 39 (6.0) 45 (5.7)
Number (%) of participants on thyroid medication 12 (8.2) 94 (14.5) 106 (13.4)
Number (%) on thyroid medication who are euthyroid 6 (50.0) 49 (52.1) 55 (51.9)
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participant was taking thyroid medication, hypothyroid
individuals did not show significant differences. However,
euthyroid individuals who were taking medication reported
four symptoms at a significantly higher prevalence than indi-
viduals who were euthyroid without medication (Additional
file 2.) These symptoms included dry skin, cold sensi-
tivity and the cognitive symptoms (slow thinking and
poor memory) at the p < 0.01 level. Hoarse voice, being
more sensitive to cold than compared to the previous year,
and constipation approached statistical significance.
Health fair participants reported a wide range of symp-
toms, from absolutely no symptoms to 30 symptoms listed
on the questionnaire (Figure 1). The median number of
symptoms reported by all health fair participants was ten,
and mean number of symptoms was eleven.
Overall we found no clinically useful predictors of
hypothyroidism among the symptoms. No individual
symptom, number of symptoms, or specific combination
of symptoms predicted TSH level. Logistic regression
analysis showed no statistically significant predictors for
hypothyroidism as defined by the upper limit of normalTable 2 Demographics by thyroid function*
Demographic Hyperthyroid TSH< 0.4 μIU/ml Eu
Age








*Percentages reported are the proportion of the health fair population (n = 794).
**Responses for Family history were not provided by seven (0.9%) participants.for the assay (TSH > 5.5 μIU/ml). Nor was there a cut
point where symptoms became significant. That is, logistic
regression showed no statistically significant predictors
with TSH >10 μIU/ml. Additionally, we repeated the
analysis with TSH level as a continuous variable, and it
did not change this finding. Neither age nor family history
correlated with TSH.Discussion and conclusions
The original goal of this project was to see if symptoms
could distinguish between people with thyroid dysfunction
and those who are euthyroid. We did not find this to
be the case in this population. No symptom, nor group
of symptoms, predicted hypothyroidism. Symptoms did
not discriminate between disease states because both
euthyroid and hypothyroid individuals reported similar
symptom prevalence. Interestingly, the euthyroid people
who presented to this thyroid screening health fair
reported a high proportion of classic thyroid symptoms,
higher than a group of euthyroid individuals in a
previously published case-control study.thyroid TSH= 0.4–5.5μIU/ml Hypothyroid TSH> 5.5 μIU/ml
20 – 87 23 -87
(51.0) (55.1)
122 (15.4%) 16 (2.0%)
524 (66.0%) 86 (10.8%)
268 (33.8%) 45 (5.7%)
373 (47.0%) 55 (6.9%)
Table 3 Participants taking/not taking thyroid hormone by thyroid function*
Hyperthyroid Euthyroid Hypothyroid
TSH < 0.4 μIU/ml TSH = 0.4 – 5.5 μIU/ml TSH > 5.5 μIU/ml
On Thyroid Not on Thyroid On Thyroid Not on Thyroid On Thyroid Not on Thyroid
26 (3.3%) 20 (2.5%) 57 (7.2%) 589 (74.2%) 25 (3.1%) 77 (9.7%)
Total 46 (5.8%) Total 646 (81.4%) Total 102 (12.8%)
*Percentages reported are the proportion of the health fair population (n = 794).
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yield of thyroid screening in this population as compared
with previous studies) found the yield of thyroid disease
on testing this group of health fair attendees higher than
previously reported in the literature [10]. This screening
program identified 97 people (12.2%) with newly diag-
nosed thyroid dysfunction, 34% of which had a TSH
greater than 10 μIU/ml. The 9.7% newly identified with
hypothyroidism greatly exceeds the prevalence rates
of hypothyroidism quoted in the literature (one to
two percent of the general population) [10]. Our rates
are higher even when the prevalence of subclinical
hypothyroid is included in the comparison studies [11].
Interestingly, the rates of an elevated TSH found in our
study are quite comparable to those reported in another
health fair population [12].
There has been much discussion regarding traditional
symptoms of thyroid disease and the utility of symptoms
in detecting hypothyroidism. Such symptoms are not
highly sensitive, though multiple investigators have tried
to quantify symptoms to aid in diagnosis [13,21-23]. As
well, symptoms may be too nonspecific to be helpful
clinically, particularly in individuals with multiple
comorbid conditions. Certainly individuals with co-Figure 1 Distribution of participants according to number of symptommorbid conditions manifest symptoms that could be
attributed to thyroid disease. Information regarding
comorbidities was not collected through the health fair,
a limitation of our study.
The prevalence that symptoms were reported by all
participants in this health fair study was considerably
higher than the prevalence of symptoms previously
reported in a case control study using the same symp-
toms questionnaire [13]. Every questionnaire symptom
was reported more often by both hypothyroid and
euthyroid participants in this screening study, than by
the euthyroid controls in the previously published study.
Several explanations are possible. Foremost, the thyroid
health fair was advertised with promotional materials
that highlighted the symptoms associated with thyroid
disease. This certainly could have attracted people with
more typical thyroid symptoms. Health fairs vary in focus
[3,4,9,24,25], and as Lefebvre and colleagues showed,
different screening offerings do attract different popula-
tions [9]. It is very likely that a health fair that advertises
thyroid screening would attract people who are concerned
about thyroid disease. Their concern may be related to
symptoms attributable to thyroid disease, or to other
factors such as family history of thyroid illness. Peoples reported.
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classically associated with thyroid dysfunction, and may
want to participate in a thyroid screening. So, the higher
prevalence of thyroid symptoms and of thyroid dysfunc-
tion found in our study may be explained by an increased
awareness of personal symptoms and the high proportion
of affected family members (42.4%). Symptom awareness
was also likely enhanced by the educational activities
during the thyroid health fair week. The increased preva-
lence of thyroid dysfunction found in our study may also
be explained in part by the fact that health fairs typically
attract individuals who are older and who are women
[5-9]. This may have contributed to our findings since
thyroid dysfunction, and hypothyroidism in particular, is
more common in older people and is nearly ten times as
common in women as in men [10]. The populations
which are at higher risk for thyroid disease are over-
represented in our health fair study (and at health fairs in
general) as compared with the general population.
It is interesting that among euthyroid individuals, some
symptoms were still reported significantly more often by
euthyroid individuals taking thyroid medication than indi-
viduals that were naturally euthyroid. Despite correcting
biochemical hypothyroidism with medication, these indi-
viduals still reported a higher prevalence of some classic
hypothyroid symptoms than biochemically euthyroid indi-
viduals who had not had thyroid disease. Whether this
reflects heightened awareness of classic symptoms of
hypothyroidism, or if it suggests that medication does not
completely reverse hypothyroid symptoms is unknown.
We also observed that almost half of the people identi-
fied as having abnormal thyroid function through this
screening program were people taking thyroid medica-
tion but who were not euthyroid despite being on treat-
ment. This finding is consistent with the literature [12],
reinforcing the need for closer monitoring of patients on
thyroid hormone replacement.
Our study was limited by free T4 levels not being avail-
able through this screening. We are therefore unable to
comment on the amount of subclinical hypothyroidism as
defined by an elevated ultrasensitive TSH but normal free
T4 level. As well, there has been discussion that the target
euthyroid TSH may actually be less than the upper limit
of the TSH assay. While multiple studies have looked at
clinical manifestations associated with these milder forms
of thyroid dysfunction, it is certainly beyond the scope of
this study. When viewed conservatively, that is at a cutoff
commonly used to represent overt disease, the nearly six
percent of the individuals we screened who had a TSH
level elevated greater than 10 μIU/ml warrants con-
sideration. Using a lower cutoff of TSH to define
hypothyroidism would only enhance the yield of testing in
our health fair population. Regarding symptoms, it is
unknown but unlikely to affect results since there were nostatistically significant differences in symptom reporting
between euthyroid and hypothyroid individuals. We are
also limited by having data from one point in time, as is
the nature of health fairs. This does not allow us to know
if any TSH results reflected transient abnormalities. How-
ever, it is unlikely that such deviations would favor abnor-
mal or normal thyroid function in particular.
Thus, testing people who wish to be evaluated for
thyroid disease can increase diagnostic yield. In our study,
testing a self-selected population increased identification
of previously unknown thyroid dysfunction from the less
than 2% quoted for the general population to 12% in this
health fair population. The observation that more disease
is identified through a disease-specific health fair than is
reported in the general population, we call the “health fair
effect”. This may reflect education about traditional
thyroid symptoms, impact of affected family members, or
the characteristics of the people themselves having more
risk factors such as age and female gender. While testing
symptomatic people may increase yield, it did not allow
discrimination between disease states in this particular
population. Traditional thyroid symptoms were highly
prevalent in all people who attended this health fair, so did
not aid in identification of disease. It is possible that
symptoms would be more discriminatory in a population
that had not been educated on thyroid dysfunction, or in a
setting outside of a health fair where people are motivated
often by risk factors for the disease being screened. The
application of symptoms to direct thyroid testing may be
better suited to a clinical setting rather than a health fair, a
possible direction for future research.
Thyroid screening does identify people who may other-
wise go undiagnosed and thus untreated, and who may
benefit from treatment because of the adverse effects of
thyroid disease on multiple organ systems. But thyroid
testing needs to be done in a setting where the chance of
identifying disease is high enough to be beneficial. Testing
a population with a likelihood of thyroid disease that is
greater than the general population, is more desirable.
The effect of this health fair was to draw a population
more likely to have thyroid disease, for several possible
reasons, and thus increase the yield of testing for thyroid
disease. Whatever drew people to have thyroid function
tested at this Thyroid Awareness health fair, resulted in an
enriched prevalence of thyroid disease. This health fair
effect may be explained by people attending the health fair
because of an increased concern for thyroid disease and
desire to be tested. Such concerns may be multifactorial,
perhaps reflecting an increased awareness of disease
symptoms because of family history of thyroid disease,
and/or the information presented by the media during
Thyroid Awareness Week. Attracting people with a high
proportion of suspect symptoms may contribute to the
health fair effect in this study. The health fair also drew a
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pants who are older than the general population. This
contributed to the health fair effect by attracting a demo-
graphic known to have a higher likelihood of thyroid
disease. Other unmeasured factors may also exist. Thus,
diagnosing previously unknown thyroid dysfunction
through testing of people who present to disease-specific
health screenings may be both effective and appropriate.
Trying to discriminate between individuals with and
without thyroid dysfunction solely based on symptoms
may be more appropriate in other settings, such as
primary care clinics. Further studies are needed to look at
the cost-effectiveness of thyroid screening in health fair
populations, and populations that resemble health fair
attendees, who have a greater likelihood of disease.
Additional files
Additional file 1: Table S1. Health Fair participants’ symptom
prevalence without significant difference; Prior Case-control euthyroid
participants’ symptom prevalence for comparison [13].
Additional file 2: Table S2. Symptom prevalence in euthyroid and
hypothyroid health fair participants, comparing those taking thyroid
medication (previously diagnosed) and those not taking thyroid
medication (new diagnosis through the health fair).
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